Belite Bio Q3 Net Loss Widens 40% to $30.3 Million

• Belite Bio’s third-quarter 2026 net loss widened 40% year over year to $30.3 million.
• Selling, general and administrative expenses rose 69% year over year to $21.4 million, primarily due to higher professional service fees.
• Research and development expenses increased 50% year over year to $15.5 million, primarily due to higher manufacturing costs, consultant fees and sponsorship funding.
• Tinlarebant’s application for Stargardt disease type 1 received FDA priority review, with a February 12, 2027, target action date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-125573), on November 12, 2026, and is solely responsible for the information contained therein.